Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19)

Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19) Patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000029626

Enrollment

Unknown

Registered

2020-02-07

Start date

2020-02-17

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Normal group:No

Severe group:No

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnosic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"; 2. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days); 3. Patients who voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with immune system diseases or cancers etc.)

Design outcomes

Primary

Measure	Time frame
TCR sequencing;BCR sequencing;HLA sequencing;	—

Countries

China

Contacts

Public ContactFang Xueling

The First Affiliated Hospital of Zhejiang University School of Medicine

13588867114@163.com+86 13588867114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026